Metazon instructions

Posted on by admin

MEZATON

1 ml - ampoules (10) - cardboard packs.

Alpha1-adrenergic stimulant, which has little effect on beta-adrenergic receptors of the heart; is not a catecholamine (contains only one hydroxyl group in the aromatic ring).

Table of contents:

Causes constriction of arterioles and increased blood pressure (with possible reflex bradycardia). Compared to norepinephrine and epinephrine, it increases blood pressure less sharply, but acts longer (less susceptible to the action of catechol-O-methyltransferase); does not cause an increase in minute blood volume.

The action begins immediately after administration and lasts for 5-20 minutes (after intravenous administration), 50 minutes (with subcutaneous administration), 1-2 hours (after intramuscular administration).

Metabolized in the liver and gastrointestinal tract (without the participation of catechol-O-methyltransferase). Excreted by the kidneys in the form of metabolites.

— shock states (including traumatic, toxic);

- vascular insufficiency (including due to an overdose of vasodilators);

- as a vasoconstrictor during local anesthesia.

- vasomotor and allergic rhinitis.

- hypersensitivity to the drug;

— hypertrophic obstructive cardiomyopathy;

Metabolic acidosis, hypercapnia, hypoxia, atrial fibrillation, angle-closure glaucoma, arterial hypertension, hypertension in the pulmonary circulation, hypovolemia, severe aortic stenosis, acute myocardial infarction, tachyarrhythmia, ventricular arrhythmia, occlusive vascular diseases (including a history) - arterial thromboembolism, atherosclerosis, thromboangiitis obliterans (Buerger's disease), Raynaud's disease, vascular tendency to spasms (including frostbite), diabetic endarteritis, thyrotoxicosis, diabetes mellitus, porphyria, glucose-6-phosphate dehydrogenase deficiency, combined use of inhibitors monoamine oxidase, under general anesthesia (fluorotane), impaired renal function, elderly age, age under 18 years (efficacy and safety have not been established).

Intravenously slowly, in case of collapse - 0.1-0.3-0.5 ml of 1% solution, diluted in 20 ml of 5% dextrose solution or 0.9% sodium chloride solution. If necessary, the administration is repeated.

Intravenous drip - 1 ml of 1% solution in ml of 5% dextrose solution.

Subcutaneously or intramuscularly, adults - 0.3-1 ml of a 1% solution 2-3 times a day; children over 15 years of age with arterial hypotension during spinal anesthesia - 0.5-1 mg/kg.

To narrow the vessels of the mucous membranes and reduce inflammation, lubricate or instill (solution concentrations - 0.125%, 0.25%, 0.5%, 1%).

For local anesthesia , add 0.3-0.5 ml of a 1% solution per 10 ml of anesthetic solution.

Higher doses for adults: subcutaneously and intramuscularly: single - 10 mg, daily - 50 mg; intravenously: single - 5 mg, daily - 25 mg.

From the cardiovascular system: increased blood pressure, palpitations, ventricular fibrillation, arrhythmia, bradycardia, cardialgia.

From the side of the central nervous system: dizziness, fear, insomnia, anxiety, weakness, headache, tremor, paresthesia, convulsions, cerebral hemorrhage.

Other: pallor of the facial skin, ischemia of the skin at the injection site, in isolated cases, necrosis and scab formation are possible when it enters the tissue or during subcutaneous injections, allergic reactions.

Symptoms: ventricular extrasystole, short paroxysms of ventricular tachycardia, a feeling of heaviness in the head and limbs, a significant increase in blood pressure.

Treatment: intravenous administration of alpha-blockers (phentolamine) and beta-blockers (for heart rhythm disturbances).

Mezaton reduces the antihypertensive effect of diuretics and antihypertensive drugs (methyldopa, mecamylamine, guanadrel, guanethidine).

Phenothiazines, alpha-blockers (phentolamine), furosemide and other diuretics reduce the antihypertensive effect.

Monoamine oxidase inhibitors (furazolidone, procarbazine, selegiline), oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenostimulants enhance the pressor effect and arrhythmogenicity of phenylephrine.

Beta-blockers reduce cardiac stimulating activity; in the presence of reserpine, arterial hypertension is possible (as a result of depletion of catecholamine reserves in adrenergic endings, sensitivity to adrenergic agonists increases). Inhalation anesthetics (chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias because they sharply increase the sensitivity of the myocardium to sympathomimetics.

Ergometrine, ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect.

Reduces the antianginal effect of nitrates, which, in turn, can reduce the pressor effect of sympathomimetics and the risk of arterial hypotension (simultaneous use is possible depending on the achievement of the required therapeutic effect).

Thyroid hormones increase (mutually) the effect and the associated risk of coronary insufficiency (especially with coronary atherosclerosis).

During the treatment period, ECG, blood pressure, minute blood volume, blood circulation in the extremities and at the injection site should be monitored.

In patients with arterial hypertension in the event of drug-induced collapse, it is sufficient to maintain systolic blood pressure at a level below the usual nammHg.

Before or during therapy for shock conditions, correction of hypovolemia, hypoxia, acidosis and hypercapnia is mandatory.

A sharp increase in blood pressure, severe bradycardia or tachycardia, persistent cardiac arrhythmias require discontinuation of treatment.

To prevent a recurrent decrease in blood pressure after discontinuation of the drug, the dose should be reduced gradually, especially after long-term infusion.

The infusion is resumed if systolic blood pressure decreases to 100 Hg.

It should be borne in mind that the use of vasoconstrictors during labor to correct arterial hypotension or as additives to local anesthetics against the background of drugs that stimulate labor (vasopressin, ergotamine, ergometrine, methylergometrine) may lead to a persistent increase in blood pressure in the postpartum period.

With age, the number of adrenergic receptors sensitive to phenylephrine decreases. Monoamine oxidase inhibitors, increasing the pressor effect of sympathomimetics, can cause headaches, arrhythmia, vomiting, hypertensive crisis, therefore, when patients take monoamine oxidase inhibitors in the previous 2-3 weeks, the dose of sympathomimetics should be reduced.

Impact on the ability to drive vehicles and operate machinery

During therapy, you should not engage in hazardous activities that require rapid motor and mental reactions (including driving a car).

Adequate and strictly controlled studies on humans and animals on the effect of the drug on pregnant women have not been conducted, there is no data on the excretion of the drug into breast milk, based on which, during pregnancy and during breastfeeding, the use of the drug is possible with caution, only under strict indications and under the supervision of a doctor , assessing the benefit-risk ratio.

Store in a place protected from light and out of reach of children at a temperature not exceeding 25°C. Shelf life: 3 years.

To ask a question about the project or contact the editors, use this form.

Source: http://health.mail.ru/drug/mesaton/

Metazon

Description current as of 12/16/2011

The drug metazon belongs to the group of alpha-adrenergic agonists. Its active ingredient is phenylephrine. Metazon is used during subdural and inhalation anesthesia, during local anesthesia as a vasoconstrictor, in acute circulatory failure, neurogenic shock, anaphylaxis, hypotension, secretory prerenal anuria, paroxysmal supraventricular tachycardia, reperfusion arrhythmias, iritis, iridocyclitis.

The drug metazone is used subcutaneously, intramuscularly, intravenously (it must be administered slowly as a stream or infusion). For intravenous injection, 10 mg of metazone is dissolved in 9 ml of water. To carry out intravenous infusion, 10 mg of metazone is added to 500 ml of 0.9% sodium chloride solution or 5% glucose. For moderate hypotension, 0.2 mg of the drug is administered intravenously, with at least 10–15 minutes between injections. For severe hypotension and shock, the drug metazone is administered intravenously. For paroxysmal supraventricular tachycardia, it is administered intravenously as a stream, and the initial dose should not exceed 0.5 mg. To use metazone as a vasoconstrictor during regional analgesia, metazone is added to the anesthesia solution at the rate of 1 mg per 20 ml.

Contraindications and side effects:

The drug Metazon should not be used by people who are highly sensitive to its components. Also contraindications are severe arterial hypertension, ventricular tachycardia, bradycardia, tendency to vasospasms, shock during myocardial infarction. The drug is not used for decompensated heart failure, conduction disorders, atherosclerosis, severe forms of coronary artery disease, damage to the cerebral arteries, acute pancreatitis and hepatitis, hyperthyroidism, arterial thrombosis, prostate hypertrophy. Metazon is contraindicated in pregnant women, children under 15 years of age and the elderly.

Side effects may include headache, agitation, irritability, feelings of dizziness and weakness, pain in the heart, hypertension, bradycardia, arrhythmia, respiratory depression, acidosis, tremor, local ischemia of the skin at the site of injection, necrosis and scab formation. provided that the drug enters the tissue.

In case of an overdose of the drug, ventricular extrasystole and paroxysms of ventricular tachycardia may occur. There is also a feeling of heaviness in the head and limbs, and a sharp increase in blood pressure. To relieve these conditions, alpha-blockers and beta-blockers are administered intravenously.

The pressor effect of metazone increases if taken in parallel with oxytocin, MAO inhibitors, tricyclic antidepressants, ergot alkaloids, and sympathomimetics. The use of metazone should not be combined with oxytocin-containing drugs to induce labor. During therapy, you should carefully monitor blood pressure, do an ECG, monitor blood circulation, and wedge pressure in the pulmonary artery. Before starting treatment with metazone, hypovolemia, acidosis, hypoxia, and hypercapnia should be corrected. If during therapy the blood pressure increases sharply, bradycardia or tachycardia, or rhythm disturbances occur, then treatment should not be continued. You cannot engage in detail associated with the need for speed of reaction and motor activity.

Source: http://medicsguru.ru/lekarstva/12007-metazon.html

Mezaton

Instructions for use:

Latin name: Mesaton

ATX code: C01CA06

Active ingredient: Phenylephrine

Analogues: Irifrin, Nazol kids

Manufacturer: GNTsLS Pilot Plant LLC (Ukraine)

Description current as of: 09.28.17

Mezaton is a vasoconstrictor drug based on phenylephrine.

Active substance

Release form and composition

Mezaton is produced by the manufacturer in the form of tablets (0.01 g), eye and nasal drops, as well as a 1% solution in ampoules.

Indications for use

Mezaton is used for collapse, arterial hypotension, various intoxications, during preparation and conduct of operations.

Mezaton nasal drops help ease nasal breathing during flu, colds, hay fever and other allergic reactions that are accompanied by acute rhinitis or sinusitis.

Mezaton eye drops are used to dilate pupils during various ophthalmological procedures, as well as for the prevention and treatment of iritis and iridocyclitis.

Contraindications

Mezaton should not be used for atherosclerosis, hypertension, acute pancreatitis, hepatitis, pheochromocytoma, ventricular fibrillation and a tendency to vascular spasms.

Intranasal use of Mezaton is unacceptable in the presence of diseases of the cardiovascular system, diabetes mellitus, thyrotoxicosis or hypertensive crisis.

Mezaton eye drops should not be prescribed for closed-angle and narrow-angle glaucoma, impaired tear production and integrity of the eyeball.

Mezaton is not recommended for use in case of hypersensitivity to its active substance, during pregnancy and lactation.

Mezaton is prescribed with caution for chronic myocardial diseases, as well as for elderly patients with hyperthyroidism.

Instructions for use Mezaton (method and dosage)

In case of collapse, Mezaton is administered slowly intravenously. To do this, 0.1-0.5 ml of the drug is diluted in 20 ml of 0.9% NaCl solution or 5% dextrose solution. If necessary, the drug is re-administered. For intravenous drip administration, 1 ml of solution must be diluted with 5% dextrose solution.

The use of Mezaton is also carried out in the form of an intramuscular or subcutaneous injection according to the following scheme: 0.3-1 ml of the drug is administered twice or three times a day.

Mezaton can be applied topically in the form of a 0.25-0.5% solution to lubricate or irrigate the mucous membranes.

Mezaton tablets instructions for use

Mezaton tablets are taken 2 or 3 times a day, 0.01-0.025 g.

Mezaton eye drops instructions for use

During ophthalmic procedures, Mezaton eye drops are administered one drop into each conjunctival sac. If necessary, the drops can be repeated after an hour. For inflammation of the choroid (uveitis), the drug is used until the inflammatory process is completed, one drop 2-3 times a day.

Nasal drops Mezaton instructions for use

Mezaton nasal drops should be instilled every 6 hours: for babies under one year old - one drop, for children aged 1-6 years - 1-2 drops, for adult patients and children over 6 years old - 3 or 4 drops in each nostril. The duration of the course of treatment does not exceed three days.

Maximum permissible doses

The maximum dose of Mezaton for internal use: single - 0.03 grams, daily - 0.15 g.

The maximum permissible doses of the drug for subcutaneous and intramuscular use: single - no more than 0.01 grams (or 1 ml of a 1% solution), daily - no more than 0.05 grams (or 5 ml of a 1% solution).

The maximum dose for intravenous use of Mezaton: single - 0.005 grams (or 0.5 ml of 1% solution), daily - no more than 0.025 grams (or 2.5 ml of 1% solution).

Side effects

The use of Mezaton may cause the following side effects:

  • From the side of the central nervous system: weakness, insomnia, dizziness, tremor, anxiety, fear, headaches, convulsions;
  • From the gastrointestinal tract: digestive problems;
  • From the cardiovascular system: arrhythmia, increased blood pressure, cardialgia, bradycardia;
  • Other effects: allergic reactions, pale skin.
  • Mezaton eye drops can provoke such adverse reactions as a burning sensation in the eyes, blurred vision, discomfort and irritation in the eyes, increased intraocular pressure, lacrimation, constriction of the pupils on the 2nd day of use.

Parenteral use of Mezaton can lead to the development of skin ischemia at the injection site, and when the drug is administered subcutaneously or the solution gets into the tissue, necrosis and scab may occur.

Intranasal use of Mezaton may cause tingling, pinching or burning in the nose.

Overdose

Symptoms: severe increase in blood pressure, short paroxysms of ventricular tachycardia, heaviness in the limbs and head, ventricular extrasystole.

Treatment: intravenous administration of beta-blockers and alpha-blockers.

Analogs

Irifrin, Nazol kids.

pharmachologic effect

Once in the human body, Mezaton stimulates the activity of alpha-adrenergic receptors, which leads to vasoconstriction, increased blood pressure, increased heart contractions, inhibition of peristalsis and dilation of the bronchi.

Mezaton drops are used in ophthalmology. They help reduce pressure inside the eye and dilate the pupils.

The active ingredient of the drug is phenylephrine hydrochloride, the effect of which on the body resembles a similar effect of adrenaline. Its advantage over adrenaline is its longer-lasting effect and the possibility of both parenteral and oral administration.

special instructions

During the course of treatment with Mezaton, it is necessary to regularly monitor ECG indicators, blood pressure, minute blood volume, as well as blood circulation at the injection site and extremities.

If there is a sharp increase in blood pressure, persistent heart rhythm disturbances, severe tachycardia or bradycardia, immediate cessation of drug treatment is required.

To prevent a repeated decrease in blood pressure after discontinuation of Mezaton, the dose of the drug should be reduced gradually, especially after a prolonged infusion. If systolic blood pressure decreases to 70–80 mmHg. Art., the infusion is resumed.

During treatment with Mezaton, it is not recommended to engage in activities that require rapid mental and motor reactions.

During pregnancy and breastfeeding

Use during pregnancy and breastfeeding is contraindicated.

In childhood

It is prescribed with special caution to children under 18 years of age.

In old age

Prescribed with extreme caution to elderly people.

For impaired renal function

It is prescribed with special caution to people with impaired renal function.

Drug interactions

Mezaton reduces the antihypertensive effect of antihypertensive drugs (mecamylamine, guanadrel, methyldopa, guanethidine) and diuretics.

Mezaton reduces the antianginal effect of nitrates, which can reduce the pressor effect of sympathomimetics and the risk of arterial hypotension.

MAO inhibitors (selegiline, procarbazine, furazolidone), oxytocin, methylphenidate, adrenergic stimulants, tricyclic antidepressants and ergot alkaloids increase the arrhythmogenicity and pressor effect of phenylephrine.

Alpha-blockers and phenothiazines reduce the hypertensive effect of Mezaton. As for beta-blockers, they reduce the pacemaker activity of phenylephrine, and while taking reserpine, arterial hypertension may develop.

Oxytocin, ergometrine, doxapram, ergotamine and methylergometrine increase the vasoconstrictor effect of the drug.

Inhalation anesthetics (isoflurane, chloroform, methoxyflurane, enflurane, halothane) increase the risk of severe ventricular and atrial arrhythmias, which is associated with a sharp increase in the sensitivity of the myocardium to sympathomimetics.

Conditions for dispensing from pharmacies

Dispensed by prescription.

Storage conditions and periods

Mezaton is stored in a place protected from light at an air temperature of no higher than 25°C. The shelf life of the drops is 2 years, and the injection solution is 3 years.

Price in pharmacies

The description posted on this page is a simplified version of the official version of the annotation for the drug. The information is provided for informational purposes only and does not constitute a guide for self-medication. Before using the medicine, you must consult a specialist and read the instructions approved by the manufacturer.

When using materials from the site, the active reference is obligatory.

The information presented on our website should not be used for self-diagnosis and treatment and cannot serve as a substitute for consultation with a doctor. We warn you about the presence of contraindications. Specialist consultation is required.

Source: http://dolgojit.net/mezaton.php

Vasoconstrictor medicine Mezaton

Mezaton is a vasoconstrictor drug that has a fairly wide range of uses.

It helps to increase heart contractions, increase blood pressure, dilate the bronchi and slow down peristalsis.

Its action is similar to adrenaline, but has a longer lasting effect.

This drug is also used in ophthalmology to reduce pressure inside the eyeball and enlarge the pupil.

1. Indications for use

Mezaton can be used in the treatment of such diseases and conditions:

  1. Arterial hypotension.
  2. Collapse.
  3. Blood loss.
  4. Intoxication of the body.
  5. Infectious diseases.
  6. Secretory renal anuria.
  7. Supraventricular paroxysmal tachycardia.
  8. This drug can be used in preparation for operations in which spinal anesthesia is used, as well as during their implementation.

In ophthalmology, Mezaton is used in the form of eye drops during therapeutic procedures to increase pupil size, as well as for the prevention and treatment of conjunctivitis, iritis and iridocyclitis.

Nasal drops are used to facilitate nasal breathing during influenza, acute respiratory viral infection, allergies, as well as other ailments in which sinusitis or rhinitis is observed.

2. Release form, composition

Mezatone can be found on sale in the form of:

  1. 1% solution for injection in glass ampoules of one milliliter. They are packaged in cardboard packages of 10 or 100 pieces. Each ampoule contains 10 milligrams of phenylephrine hydrochloride, water for injection and glycerin.
  2. A 2.5% solution, which is drops into the nose or eyes in 5 ml bottles. 1 milliliter of this solution contains 25 milligrams of phenylephrine hydrochloride, purified water, decamethoxin, Trilon B and polyethylene oxide 400.
  3. Tablets of 0.01 grams - 10 pieces per package.

3. Method of application

In case of collapse, Mezaton should be carefully injected into a vein, before diluting 0.1-0.5 milliliters of the above-mentioned drug in 20 milliliters of a 0.9% NaCl solution or a 5% dextrose solution. If necessary, another administration of the drug can be performed.

For intravenous administration using a dropper, 1 milliliter of Mezaton is dissolved in milliliters of 5% dextrose solution.

From 0.3 to 1 milliliter of Mezaton can also be used in the form of a subcutaneous or intramuscular injection three times a day.

In tablets, this medicine is prescribed at 0.01-0.025 grams twice or thrice throughout the day.

This drug can be used topically for spraying or coating the mucous membranes in the form of a 0.25-0.5% solution.

Mezaton nasal drops should be instilled at intervals of six hours. A single dosage for children under one year of age is one drop, for children from one to six years of age - one or two drops, and for children over six years of age and for adults - three or four drops in each nostril. The treatment course should last no more than three days.

During ophthalmological procedures, eye drops should be dropped one drop at a time into both conjunctival sacs, and after an hour they can be dropped again.

To treat inflammation of the choroid, Mezaton is instilled one drop two or three times throughout the day.

When taken orally, a single dose of Mezaton should not be more than 0.03 grams, and a daily dose should not be more than 0.15 grams. When administering this drug intravenously, the maximum permitted dose per day should not be more than 0.025 grams, and a one-time dose should not be more than 0.005 grams. If administered subcutaneously or intramuscularly, a single dose of Mezaton should be no more than 0.01 grams, and a daily dose should be no more than 0.05 grams.

4. Interaction with other drugs

In the case of parallel use of Mezaton with diuretics and drugs to lower blood pressure, their hypotensive effect is reduced.

If Mezaton is used in parallel with inhalational anesthetics, the risk of developing severe ventricular or atrial arrhythmia increases.

The use of the above drug together with monoamine oxidase inhibitors, ergot alkaloids, oxytocin, adrenergic stimulants, tricyclic antidepressants and methylphenidate leads to an increase in the arrhythmogenicity and pressor effect of phenylephrine.

The use of Mezaton with phenothiazines and alpha-blockers helps to weaken their hypertensive effect, and its combined use with reserpine can provoke the development of arterial hypertension.

5. Side effects

The following side effects of using Mezaton may occur on the part of the nervous system:

The organs of the cardiovascular system can respond to taking this drug with the following conditions:

  1. Bradycardia.
  2. Cardialgia.
  3. Increased blood pressure.
  4. Arrhythmia.
  5. Accelerated heartbeat.
  6. Ventricular fibrillation.
  7. Digestive problems, allergic reactions and pale skin may also occur.

Eye drops can cause side effects such as:

  1. Blurred vision.
  2. Feeling of discomfort.
  3. A burning sensation in the eyes.
  4. Increased tear production.
  5. Increased intraocular pressure.
  6. The next day after use, your pupils may become constricted.

When used parenterally, ischemia of the skin in the injection area may be observed, and when the drug is administered subcutaneously, eschar and necrosis sometimes occur, which is evidence of the drug entering the tissue.

Nasal drops may cause a burning, tingling, or tingling sensation inside the nose.

6. Contraindications

All contraindications to the use of the above-mentioned medicine can be divided into absolute, in which its use is unacceptable, and relative, in which the drug must be used with caution, since there is a risk of complications.

Absolute contraindications include:

  1. Ventricular fibrillation.
  2. Hypersensitivity to the components of the drug.
  3. Pheochromocytoma.
  4. Hypertrophic obstructive cardiomyopathy.
  5. Hepatitis.
  6. Pancreatitis.

Relative contraindications are:

  1. Renal dysfunction.
  2. Advanced age.
  3. Children under eighteen years of age.
  4. General anesthesia using fluorotan.
  5. Concurrent use of monoamine oxidase inhibitors.
  6. Arterial hypertension.
  7. Hypertension in the pulmonary circulatory system.
  8. Metabolic acidosis.
  9. Hypoxia.
  10. Atrial fibrillation.
  11. Acute myocardial infarction.
  12. Complex stenosis of the aortic mouth.
  13. Hypovolemia.
  14. Hypercapnia.
  15. Tachyarrhythmia.
  16. Buerger's disease.
  17. Atherosclerosis.
  18. Thromboembolism of arteries.
  19. Raynaud's disease.
  20. Porphyria.
  21. Diabetes.
  22. Susceptibility of blood vessels to spasms.
  23. Thyrotoxicosis.
  24. Diabetic endarteritis.
  25. Lack of glucose-6-phosphate dehydrogenase.

Eye drops are not recommended for use if:

  1. Violation of tear production and integrity of the eyeball.
  2. The presence of closed-angle and narrow-angle glaucoma.

During pregnancy

Pregnancy and breastfeeding are not contraindications to the use of Mezaton.

However, at this time it can be used only after consultation with the treating specialist and the balance between the expected benefit and the existing risk.

7. Storage conditions and periods

Mezaton should be kept in a place hidden from sunlight, where the air temperature does not exceed 25 degrees Celsius.

The shelf life of the drops is two years, and the solution for injection is three years. The drug should be kept away from children.

8. Price

In pharmacies of the Russian Federation, Mezaton ampoules with injection solution can be purchased for 40 rubles, and eye drops for 160 rubles.

In pharmacies located in Ukraine, the average cost of eye drops called Mezaton is 30 hryvnia, and ampoules with an injection solution are 20 hryvnia.

9. Analogs

The following drugs can be called analogues of Mezaton:

10. Reviews

On the Internet you can find both neutral and positive reviews about Mezatone. The main advantage of this drug is its affordable price.

Some patients praise Mezaton for helping them normalize their blood pressure. As for eye drops, patients note many side effects of this drug.

If you want to read reviews from real people who have used Mezaton, you can find them at the end of the article.

11. Conclusion:

  1. Mezaton is a broad-spectrum vasoconstrictor.
  2. It is available in the form of eye and nasal drops, injection solution, and tablets.
  3. When using Mezaton, various side effects may occur.
  4. Mezaton can be taken during pregnancy and lactation strictly as prescribed by a doctor.
  5. There are some analogues of Mezaton.
  6. The cost of Mezaton is quite affordable.

12. Test. Are you a sensitive or carefree person?

Most diseases of the cardiovascular system are caused by stress, find out how sensitive you are to environmental factors:

Source: http://upheart.org/lechenie/ampuly/sosudosuzhivayushchee-lekarstvo-mezaton.html

Mezaton

Instructions for use:

Mezaton is a drug with vasoconstrictor and alpha-adrenomimetic effects.

Release form and composition

Mezaton is available in the form of an injection solution: transparent, colorless (1 ml in ampoules, 10 ampoules in a cardboard pack, complete with a ceramic cutting disc or ampoule scarifier).

Active ingredient: phenylephrine hydrochloride, 1 ml – 10 mg.

Auxiliary components: injection water and glycerin.

Indications for use

  • Vascular insufficiency (including due to an overdose of vasodilators);
  • Arterial hypotension;
  • Allergic and vasomotor rhinitis;
  • Shock conditions, including toxic and traumatic shock.

In addition, Mezaton is used during local anesthesia as a vasoconstrictor.

Contraindications

  • Hypertrophic obstructive cardiomyopathy;
  • Ventricular fibrillation;
  • Pheochromocytoma;
  • Hypersensitivity to the drug.

Relative (special care should be taken due to the risk of complications):

  • Arterial hypertension, hypertension in the pulmonary circulation, atrial fibrillation, ventricular arrhythmia, acute myocardial infarction, severe aortic stenosis, angle-closure glaucoma, hypoxia, hypovolemia, hypercapnia, tachyarrhythmia, metabolic acidosis;
  • Occlusive vascular diseases (including a history): Buerger's disease (thromboangiitis obliterans), atherosclerosis, Raynaud's disease, arterial thromboembolism, vascular tendency to spasms (including frostbite), porphyria, diabetes mellitus, glucose-6 deficiency phosphate dehydrogenase, thyrotoxicosis, diabetic endarteritis;
  • Concomitant use of monoamine oxidase inhibitors (MAO);
  • Functional kidney disorders;
  • General fluorotane anesthesia;
  • Age up to 18 years;
  • Elderly age.

Pregnant and breastfeeding women can be prescribed Mezaton only according to strict indications, after assessing the balance of benefits and possible risks.

Directions for use and dosage

Mezaton solution is administered intravenously (stream or drip), intramuscularly or subcutaneously.

In case of collapse, it is administered intravenously in a slow stream at a dose of 0.1-0.3-0.5 ml, having previously diluted 20 ml of 0.9% sodium chloride solution or 5% dextrose solution. If necessary, another dose is administered.

The drug is administered intravenously in a dose of 1 ml, pre-diluted with a 5% dextrose solution.

Mezaton is prescribed intramuscularly or subcutaneously for adults at a dose of 0.3-1 ml 2-3 times a day, for children over 15 years of age with arterial hypotension during spinal anesthesia - at a dose of 0.5-1 mg per kilogram of body weight.

To reduce inflammation and constriction of blood vessels in the mucous membranes, the drug (at concentrations of 0.125, 0.25, 0.5, 1%) is used for lubrication or instillation.

When performing local anesthesia, for every 10 ml of anesthetic solution, add 0.3-0.5 ml of a 1% Mezaton solution.

Maximum permissible doses for adults:

  • Intravenous: single – 5 mg, daily – 25 mg;
  • Intramuscular and subcutaneous: single dose – 10 mg, daily dose – 50 mg.

Side effects

  • Cardiovascular system: increased blood pressure, rapid heartbeat, arrhythmia, ventricular fibrillation, cardialgia, bradycardia;
  • Central nervous system: insomnia, fear, anxiety, dizziness, weakness, paresthesia, tremor, convulsions, headache, cerebral hemorrhage;
  • Other: skin ischemia at the injection site, facial skin pallor; in isolated cases - allergic reactions, scab formation and necrosis (with subcutaneous injections and if the solution gets into the tissue).

special instructions

During treatment, it is necessary to monitor electrocardiogram indicators, blood pressure, blood circulation at the injection site and extremities, and minute blood volume.

Before or during treatment of shock conditions, correction of hypoxia, hypovolemia, hypercapnia and acidosis is required.

In the case of drug-induced collapse in patients with arterial hypertension, it is sufficient to maintain systolic blood pressure at a level below the usual nammHg.

Persistent heart rhythm disturbances, severe tachycardia or bradycardia, and a sharp increase in blood pressure require discontinuation of Mezaton.

To prevent a repeated decrease in blood pressure after discontinuation of the drug, it is recommended to reduce the dose gradually, especially after long-term infusion. However, if systolic blood pressure decreases to mmHg, the infusion is resumed.

It should be borne in mind that vasoconstrictors used in addition to local anesthetics simultaneously with drugs that stimulate labor (ergotamine, vasopressin, methylergometrine, ergometrine), or intended to correct arterial hypotension during labor, may lead to a persistent increase in blood pressure in the postpartum period .

With age, the number of adrenergic receptors sensitive to phenylephrine decreases. MAO inhibitors, increasing the pressor effect of sympathomimetics, can contribute to the appearance of vomiting, the development of arrhythmia, headaches, and hypertensive crisis. For this reason, patients who have taken MAO inhibitors in the previous 2-3 weeks should have their sympathomimetic doses reduced.

During the period of treatment with Mezaton, it is necessary to refrain from engaging in activities that require speed of mental and motor reactions, including driving.

Drug interactions

Possible interaction reactions in case of simultaneous use of Mezaton and other drugs:

  • Antihypertensive drugs, diuretics: reducing their hypotensive effect;
  • Monoamine oxidase inhibitors (procarbazine, furazolidone, selegiline), tricyclic antidepressants, ergot alkaloids, adrenergic stimulants, methylphenidate, oxytocin: increased pressor effect and arrhythmogenicity of phenylephrine;
  • Inhalation anesthetics (halothane, enflurane, methoxyflurane, isoflurane, chloroform): increased risk of developing severe ventricular and atrial arrhythmias;
  • Nitrates: reducing their antianginal effect, reducing the pressor effect of phenylephrine, the risk of developing arterial hypotension;
  • Thyroid hormones: synergistic effect of drugs and an increase in the associated risk of developing coronary insufficiency, especially in patients with coronary atherosclerosis;
  • Alpha-blockers, phenothiazines: decreased hypertensive effect;
  • Methylergometrine, doxapram, ergotamine, oxytocin, ergometrine: increased severity of vasoconstrictor action;
  • Beta-blockers: decreased cardiac stimulating activity; when using reserpine there is a risk of developing arterial hypertension.

Analogs

Analogues of Mezaton are: Irifrin 2.5%, Nazol kids spray.

Terms and conditions of storage

Store at temperatures up to 25ºC. Do not expose to light. Keep away from children.

Shelf life – 3 years.

Conditions for dispensing from pharmacies

Dispensed by prescription.

Information about the drug is generalized, provided for informational purposes and does not replace official instructions. Self-medication is dangerous to health!

The cough medicine “Terpinkod” is one of the top sellers, not at all because of its medicinal properties.

The first vibrator was invented in the 19th century. It was powered by a steam engine and was intended to treat female hysteria.

According to statistics, on Mondays the risk of back injuries increases by 25%, and the risk of a heart attack by 33%. Be careful.

When lovers kiss, each of them loses 6.4 calories per minute, but at the same time they exchange almost 300 types of different bacteria.

During operation, our brain expends an amount of energy equal to a 10-watt light bulb. So the image of a light bulb above your head at the moment an interesting thought arises is not so far from the truth.

Each person has not only unique fingerprints, but also tongue prints.

Human bones are four times stronger than concrete.

The highest body temperature was recorded in Willie Jones (USA), who was admitted to the hospital with a temperature of 46.5°C.

Millions of bacteria are born, live and die in our intestines. They can only be seen under high magnification, but if they were put together, they would fit in a regular coffee cup.

Our kidneys are capable of purifying three liters of blood in one minute.

Four pieces of dark chocolate contain about two hundred calories. So if you don’t want to gain weight, it’s better not to eat more than two slices a day.

Human blood “runs” through the vessels under enormous pressure and, if their integrity is violated, it can shoot at a distance of up to 10 meters.

An educated person is less susceptible to brain diseases. Intellectual activity promotes the formation of additional tissue that compensates for the disease.

People who eat breakfast regularly are much less likely to be obese.

A job that a person doesn’t like is much more harmful to his psyche than no job at all.

Omissions, disagreements, maiden name... Women's jealousy is a mystery for psychologists. Today, scientists do not fully know all the mechanisms that give rise to this strong and ra.

Source: http://www.neboleem.net/mezaton.php

Mezaton - official instructions for use

on medical use of the drug

Trade name of the drug: Mezaton

International nonproprietary name:

Dosage form:

Compound:

1 ml of solution contains:

active substance phenylephrine hydrochloride - 10 mg;

excipients: glycerin, water for injection.

Description: transparent colorless liquid.

Pharmacotherapeutic group:

Synthetic alpha 1-adrenergic stimulant, which has little effect on cardiac beta-blockers; is not a catecholamine (contains only one hydroxyl group in the aromatic ring). Causes constriction of arterioles and an increase in blood pressure (BP) with possible reflex bradycardia. Compared to norepinephrine and epinephrine, the increase in blood pressure is less dramatic, but lasts longer (it is less susceptible to the action of catechol-O-methyltransferase) and does not cause an increase in minute blood volume. The action begins immediately after administration and continues for 20 minutes (after intravenous administration), 50 minutes (with subcutaneous administration), 1-2 hours (after intramuscular injection).

Metabolized in the liver and gastrointestinal tract (without the participation of catechol-O-methyltransferase). Excreted by the kidneys in the form of metabolites.

Collapse, arterial hypotension (associated with decreased vascular tone), in preparation for surgery and during operations, vasomotor and hay rhinitis, intoxication, as a vasoconstrictor during local anesthesia

Hypersensitivity to the drug, hypertrophic obstructive cardiomyopathy (including asymmetric septal hypertrophy), pheochromocytoma, tachyarrhythmia, atrial and/or ventricular fibrillation, metabolic acidosis, hypercapnia, hypoxia, arterial hypertension, hypertension in the pulmonary circulation, hypovolemia, severe stenosis aortic orifice, acute myocardial infarction, porphyria. congenital deficiency of glucose-6-phosphate dehydrogenase, tendency to vascular spasms, pregnancy, lactation, age under 18 years (efficacy and safety have not been established).

With caution: Prinzmetal's angina, history of occlusive vascular diseases, including arterial thromboembolism, atherosclerosis, thromboangiitis obliterans (Buerger's disease), frostbite, diabetic endarteritis, Raynaud's disease, thyrotoxicosis, old age, diabetes mellitus, under general anesthesia (fluorotane), renal dysfunction.

Directions for use and doses

In order to narrow the vessels of the mucous membranes of the nasal cavity and reduce the severity of inflammation, 0.25-0.5% solutions are instilled or the mucous membranes are lubricated with these solutions. To local anesthetics (per 10 ml of anesthetic solution) add 0.3-0.5 ml of 1% Mezaton solution.

Higher doses for adults: intravenous - single 0.005 g, daily - 0.025 g; subcutaneously and intramuscularly - one-time 0.01 g, daily - 0.05 g.

From the cardiovascular system: increased blood pressure, palpitations, ventricular fibrillation, arrhythmia, bradycardia, cardialgia.

From the gastrointestinal tract: dyspeptic symptoms;

From the central nervous system: dizziness, fear, insomnia, anxiety, weakness, headache, tremor, paresthesia, convulsions, cerebral hemorrhage;

Other: pallor of the facial skin, ischemia of the skin at the injection site, in isolated cases, necrosis and scab formation are possible when it enters the tissue or during subcutaneous injections, allergic reactions.

Symptoms: ventricular extrasystole, short paroxysms of ventricular tachycardia, a feeling of heaviness in the head and limbs, a significant increase in blood pressure.

Treatment: intravenous administration of alpha-blockers (phentolamine) and beta-blockers (for heart rhythm disturbances).

Interaction with other drugs

Phenothiazines, alpha-blockers (phentolamine), Furosemide and other diuretics reduce the hypertensive effect.

Monoamine oxidase inhibitors, oxytocin, ergot alkaloids, tricyclic antidepressants, furazolidine, procarbazine, selegiline, adrenergic stimulants increase the pressor effect, and the latter also increase arrhythmogenicity.

Beta-blockers reduce cardiac stimulating activity, and with reserpine, arterial hypertension is possible (due to depletion of catecholamine reserves in adrenergic endings, sensitivity to adrenergic agonists increases).

During the treatment period, ECG, blood pressure, minute blood volume, blood circulation in the extremities and at the injection site should be monitored.

Before starting or during therapy, correction of hypovolemia, hypoxia, acidosis, and hypercapnia is required.

A sharp increase in blood pressure, severe bradycardia or tachycardia, persistent cardiac arrhythmias require discontinuation of treatment. To prevent a recurrent decrease in blood pressure after discontinuation of the drug, the dose should be reduced gradually, especially after long-term infusion. The infusion is resumed if systolic blood pressure decreases to 100 m Hg. Art.

During therapy, you should not engage in hazardous activities that require rapid motor and mental reactions (including driving a car).

1 ml in ampoules, enclosed in 10 pieces together with instructions for use and an ampoule scarifier in a cardboard pack.

List B. In a place protected from light and out of reach of children, at a temperature not exceeding 25°C.

Do not use the drug after the expiration date indicated on the package!

LLC "Experimental plant "GNTsLS" Address: Ukraine, 61057, Kharkov, st. Vorobyova, 8

Source: http://medi.ru/instrukciya/mezaton_1280/

Mezaton: instructions for use

Compound

Description

pharmachologic effect

Mezaton belongs to the group of adrenomimetic substances - stimulants of a-adrenergic receptors; has little effect on the beta-adrenergic receptors of the heart. Constricts the arterioles and increases blood pressure, has virtually no effect on the amount of cardiac output. Causes dilation of the pupils (less lasting than with the action of atropine and without affecting accommodation); in open-angle glaucoma it can reduce intraocular pressure. It is more resistant than catecholamines to the action of catechol-o-methyltransferase, which explains its longer-lasting effects.It is well absorbed both when taken orally and when administered parenterally.

Pharmacokinetics

The drug quickly enters the body tissues. Biotransformed under the influence of MAO to inactive metabolites, excreted mainly in the urine. The effect lasts 20 minutes when administered intravenously, and minutes when administered subcutaneously. The pharmacokinetics of mezatone in patients with dysfunction of the elimination organs (liver, kidneys) have not been studied.

Indications for use

Arterial hypotension, shock conditions (including traumatic, toxic), vascular insufficiency (including against the background of an overdose of vasodilators), as a vasoconstrictor during local anesthesia.

Contraindications

Hypersensitivity to the components of the drug, all types of arterial hypertension, cardiosclerosis, halothane or cyclopropane anesthesia, hypertrophic cardiomyopathy, pheochromocytoma, ventricular fibrillation, occlusive vascular diseases: arterial thromboembolism, atherosclerosis, thromboangiitis obliterans (Buerger's disease), Raynaud's disease, predisposition to spasms during frostbite, diabetic endarteritis; thyrotoxicosis, age under 18 years, pregnancy, lactation, old age.

Carefully. The drug is used with caution in metabolic acidosis, hypercapnia, all types of hypoxia, atrial fibrillation, angle-closure glaucoma, hypertension in the pulmonary circulation, hypovolemia, severe aortic stenosis, coronary heart disease, acute myocardial infarction, tachyarrhythmia, ventricular arrhythmia.

Pregnancy and lactation

Adequate and strictly controlled studies in humans and animals on the effect of the drug on pregnant women have not been conducted. There is no information on the ability of the drug to pass into breast milk. Based on this, the drug is contraindicated during pregnancy and lactation. If it is necessary to use the drug during lactation, breastfeeding is interrupted.

Directions for use and doses

The drug is administered intravenously, subcutaneously, intramuscularly.

In case of acute decrease in blood pressure, the drug is administered, as a rule, intravenously in doses of 0.1-0.3-0.5 ml of a 1% solution in 20 ml of 5%-20% glucose solutions, or in the same volumes of isotonic sodium chloride solution. The administration is carried out slowly, the administration is repeated if necessary. When using the drip method, 1 ml of 1% Mezaton solution is administered in 5% glucose solution. Adults are administered subcutaneously and intramuscularly in doses of 0.3-1 ml of a 1% solution. To local anesthetics (per 10 ml of anesthetic solution) add 0.3-0.5 ml of 1% Mezaton solution.

Higher doses for adults: intravenously - single 0.005 g, daily 0.025 g; subcutaneously and intramuscularly - one-time 0.01 g, daily 0.05 g.

In persons with impaired liver and kidney function, no dose adjustment is required.

Side effect

From the cardiovascular system: attacks of angina pectoris, tachycardia, bradycardia, increased or decreased blood pressure, cerebral hemorrhage, ventricular arrhythmia (especially when used in high doses), pale facial skin.

From the nervous system: headache, dizziness, irritability, fear, anxiety, weakness, tremor, convulsions.

From the gastrointestinal tract: nausea, vomiting, dyspepsia.

From the respiratory system: dyspnea.

Allergic reactions: skin rash, itching.

Overdose

Possible increased side effects of the drug, ventricular extrasystole, short paroxysms of ventricular tachycardia, sensations of heaviness in the head and limbs, increased blood pressure, dizziness.

Treatment: intravenous administration of short-acting alpha-blockers (phentolamine). In case of heart rhythm disturbances, beta-blockers (propranolol) are administered.

Interaction with other drugs

The vasoconstrictor effect of Mezaton is weakened when combined with chlorpromazine and other phenothiazine derivatives.

When used together with furazolidone, Mezaton can cause a hypertensive crisis due to the rapid release of norepinephrine.

Mezaton reduces the hypotensive effect of diuretics and antihypertensive drugs.

MAO inhibitors, increasing the pressor effect of sympathomimetics, can cause headaches, arrhythmia, vomiting, hypertensive crisis, therefore, when patients take MAO inhibitors in the previous 2-3 weeks. doses of sympathomimetics should be reduced.

Oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenomimetics enhance the pressor effect and arrhythmogenicity of Mezaton.

Beta-blockers reduce the cardiac stimulating activity of the drug. The use of the drug while previously taking reserpine can cause the development of a hypertensive crisis due to the depletion of catecholamine reserves in adrenergic endings and increased sensitivity to adrenergic agonists.

Inhalation anesthetics (including chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias because they sharply increase the sensitivity of the myocardium to sympathomimetics.

Ergometrine, ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect.

Mezaton reduces the antianginal effect of nitrates, which, in turn, can reduce the pressor effect of Mezaton and the risk of arterial hypotension (simultaneous use is allowed depending on the achievement of the required therapeutic effect).

Thyroid hormones increase (mutually) the effectiveness of the drug and the associated risk of coronary insufficiency (especially with coronary atherosclerosis). The use of Mezaton during childbirth to correct arterial hypotension against the background of the use of drugs that stimulate labor (vasopressin, ergotamine, ergometrine, methylergometrine) can cause a persistent increase in blood pressure in the postpartum period.

Precautionary measures

During the treatment period, ECG, blood pressure, blood flow, blood circulation in the extremities and at the injection site should be monitored.

In patients with arterial hypertension in the event of drug-induced collapse, it is sufficient to maintain systolic pressure at a level below the usual nammHg. Art.

Before starting or during therapy for shock conditions, correction of hypovolemia, hypoxia, acidosis or hypercapnia is mandatory.

A sharp increase in blood pressure, severe bradycardia or tachycardia, persistent cardiac arrhythmias require discontinuation of treatment.

To prevent a recurrent decrease in blood pressure after discontinuation of the drug, the dose should be reduced gradually, especially after long-term infusion. The infusion is resumed if systolic blood pressure decreases to 100 m Hg. Art.

It should be borne in mind that the use during treatment of vasoconstrictors during labor to correct arterial hypotension or as additives to local anesthetics against the background of drugs that stimulate labor (vasopressin, ergotamine, ergometrine, methylergometrine) may lead to a persistent increase in blood pressure in the postpartum period .

With age, the number of adrenergic receptors sensitive to phenylephrine decreases.

Release form

1 ml in ampoules, 10 ampoules per pack.

Storage conditions

Best before date

Conditions for dispensing from pharmacies

Mezaton analogues, synonyms and group drugs

You should consult your doctor and read the instructions before use.

Source: http://apteka.103.by/mezaton-instruktsiya/